Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Castle Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CSTL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CSTL's weekly volatility (11%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CSTL exceeded the US Healthcare industry which returned 39.4% over the past year.
Return vs Market: CSTL underperformed the US Market which returned 50.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Castle Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDoes This Valuation Of Castle Biosciences, Inc. (NASDAQ:CSTL) Imply Investors Are Overpaying?
1 month ago | Simply Wall StHave Insiders Been Selling Castle Biosciences, Inc. (NASDAQ:CSTL) Shares This Year?
3 months ago | Simply Wall StAnnouncing: Castle Biosciences (NASDAQ:CSTL) Stock Increased An Energizing 166% In The Last Year
Is Castle Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CSTL ($55.17) is trading above our estimate of fair value ($10.17)
Significantly Below Fair Value: CSTL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CSTL is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: CSTL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CSTL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CSTL is good value based on its PB Ratio (3.3x) compared to the US Healthcare industry average (3.5x).
How is Castle Biosciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSTL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CSTL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CSTL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CSTL's revenue (30% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: CSTL's revenue (30% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CSTL is forecast to be unprofitable in 3 years.
How has Castle Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSTL is currently unprofitable.
Growing Profit Margin: CSTL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CSTL is unprofitable, but has reduced losses over the past 5 years at a rate of 78% per year.
Accelerating Growth: Unable to compare CSTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CSTL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (59.7%).
Return on Equity
High ROE: CSTL has a negative Return on Equity (-3.62%), as it is currently unprofitable.
How is Castle Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: CSTL's short term assets ($426.7M) exceed its short term liabilities ($17.6M).
Long Term Liabilities: CSTL's short term assets ($426.7M) exceed its long term liabilities ($1.2M).
Debt to Equity History and Analysis
Debt Level: CSTL is debt free.
Reducing Debt: CSTL had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CSTL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CSTL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 132.2% per year.
What is Castle Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CSTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CSTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CSTL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CSTL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CSTL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Derek Maetzold (58 yo)
Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. Mr. Maetzold served as the Vice Presi...
CEO Compensation Analysis
Compensation vs Market: Derek's total compensation ($USD5.34M) is above average for companies of similar size in the US market ($USD3.78M).
Compensation vs Earnings: Derek's compensation has increased whilst the company is unprofitable.
Experienced Management: CSTL's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: CSTL's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.5%.
Castle Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Castle Biosciences, Inc.
- Ticker: CSTL
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$1.382b
- Shares outstanding: 25.06m
- Website: https://castlebiosciences.com
Number of Employees
- Castle Biosciences, Inc.
- 820 South Friendswood Drive
- Suite 201
- United States
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a mul...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 00:00|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.